Exclusive Summary

• - Strong IP in US/EU/JP persists; earliest broad generic opportunities cluster in 2026–2030 across non‑SPC and emerging markets.
• - Targets EGFR-mutant (ex19del/L858R) advanced NSCLC with an estimated 300–450k first-line eligible patients/year globally, heavily concentrated in East Asia.
• - ARCHER 1050 shows superior PFS/OS over gefitinib, making it a cost-effective alternative where osimertinib access is limited.
• - As of 2024, no FDA/EMA generic is publicly listed, so competitive intensity is low and early distributor partnerships can secure first-mover advantage.
• - If backed by EU-GMP/US-FDA compliance and full CTD/BE package, the product can enter multi-region tenders quickly and be priced 70–90% below originator.